Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GIFT Study: Genetic Testing Viable For Personalizing Antiplatelet Therapy

This article was originally published in The Gray Sheet

Executive Summary

A recent study supports a role for genetic testing as a means of personalizing antiplatelet therapy following stent placement and builds the case that newer drugs, such as Eli Lilly/Daiichi Sankyo's Effient (prasugrel), are more appropriate options for those who have poor response to standard Plavix (clopidogrel) treatment.

You may also be interested in...



Tgen, Dell Partner To Combine Genomics With Cloud Computing For Personalized Medicine

Two trials testing Tgen’s approach to using genomics algorithms to help select cancer treatments are ongoing. The further ambition is to unite outcomes data in electronic health records and genomics data to get an even more personalized view of what’s going on with a patient.

TCT Late-Breaker: Point-Of-Care Genetic Test Guides Antiplatelet Therapy

Data presented at TCT may support rapid, point-of-care genetic testing in tailoring antiplatelet therapy, but clinicians are still not convinced.

TCT Late-Breaker: Point-Of-Care Genetic Test Guides Antiplatelet Therapy

Data presented at the Transcatheter Cardiovascular Therapeutics meeting may support rapid, point-of-care genetic testing in tailoring antiplatelet therapy, but clinicians are still not convinced.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT030044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel